Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Combination therapy with α-CTLA-4 and α-PD-1 has shown significant clinical responses in different types of cancer. However, the underlying mechanisms remain elusive. Here, combining detailed analysis of human tumour samples with preclinical tumour models, we report that concomitant blockade of CTLA-4 and PD-1 improves anti-tumour immune responses and synergistically eradicates tumour. Mechanistically, combination therapy relies on the interdependence between IL-7 and IFN-γ signalling in T cells, as lack of either pathway abrogates the immune-boosting and therapeutic effects of combination therapy. Combination treatment increases IL-7Rα expression on tumour-infiltrating T cells in an IFN-γ/IFN-γR signalling-dependent manner, which may serve as a potential biomarker for clinical trials with immune checkpoint blockade. Our data suggest that combining immune checkpoint blockade with IL-7 signalling could be an effective modality to improve immunotherapeutic efficacy. Taken together, we conclude that combination therapy potently reverses immunosuppression and eradicates tumours via an intricate interplay between IFN-γ/IFN-γR and IL-7/IL-7R pathways.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with these findings, microbes may reverse the resistance to immunotherapy through reactivation of IFN-ɤ signaling pathways.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [94]
Experimental — accuracy not yet measuredIn the citing paper
“CTLA-4 blocking therapy of tumor-bearing mice also reportedly improves IFN-ɤ signaling in T cells (94).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“We previously found that a -CTLA-4 blockade inhibits tumour growth and promotes tumour-free survival of tumour-bearing mice 4 , contributing to the recent FDA approval of ipilimumab, a human a -CTLA-4 monoclonal antibody that improves overall survival in patients with metastatic melanoma 5,6 .”
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“On a side note, identification of biomarkers that can predict which patients respond to cancer immunotherapy is an active research area 45 .”
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 1×
“These findings, together with recent reports that blocking the PD-1/PD-L1 pathway improves overall survival and objective responses in patients with metastatic melanoma 7,8 , helped to establish a new field of ‘immune checkpoint blockade’.”
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 1×
“IHC staining with PD-1 and PD-L1 staining has been described previously 55–57 .”
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“A cardinal feature of immune checkpoint therapy is the induced durability of tumour rejection responses 2 .”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 1×
“We previously found that a -CTLA-4 blockade inhibits tumour growth and promotes tumour-free survival of tumour-bearing mice 4 , contributing to the recent FDA approval of ipilimumab, a human a -CTLA-4 monoclonal antibody that improves overall survival in patients with metastatic melanoma 5,6 .”
Cited by
Items 101–113 of 113
Interleukin-7Rα in the regulation of lymphoid anti-viral responses and homeostasis
Sheikh, A. (2021) · cIRcle (University of British Columbia) · doi:10.14288/1.0402591
Sharma, P., Anandhan, S., Siddiqui, B. A., Goswami, S., Subudhi, S. K., Gao, J., Peggs, K. S., Quezada, S. A., & Allison, J. P. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm068.pub2
Self-citationCD4 + T-cell immunity of SARS-CoV-2 patients determine pneumonia developmentPreprint
Naito, E., Uchida, T., Yamasaki, S., Hashimoto, K., Miura, Y., Shiono, A., Kawamura, T., Mouri, A., Yamaguchi, O., Imai, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.31.543129
Lalle, G. (2022) · theses.fr (ABES) · doi:10.70675/0ac23c2az7dcdz48eeza1dbz05a60e97e55e
Effet du microbiote intestinal sur la pharmaco-onco-immunologie des statines
Pukar, K. C. (2020) · theses.fr (ABES) · doi:10.70675/ff8b34e6z83e6z4a77z8a50z14b3a52080e9
Impact of Concurrent Antibiotic & Corticosteroid Use on Efficacy of Immune Checkpoint Inhibitors
Tran, D. (2023) · University of Minnesota Digital Conservancy (University of Minnesota) · Cited by 2
Yang, J., Li, Y., Kumar, S. V., Saba, N. F., Shay, C., & Teng, Y. (2026) · Biomarker Research · doi:10.1186/s40364-026-00955-7
“However, IFN-γ is required for this reversal, and mtDNA stress can adjust PD-L1 expression via cGAS-STING signaling, negatively affecting immunotherapy efficacy [111–113].”
Deluce, N. K.-N., Creton, E., Savatier, A., Lucchi, H., Bardouillet, L., Ramos, O. H. P., Berthon, P., & Léonetti, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1734778
“The fi rst model used was MB49 bladder cancer, which displays ‘ desert ’ characteristics, featuring a low proportion of T lymphocytes and a high proportion of myeloid-derived suppressor cells (MDSCs) (32), yet can still be controlled by standard anti-immune checkpoint antibodies (33).”
Inomata, M., Moriyasu, Y., Tsuda, T., Umeda, Y., Yoneda, T., Takahara, Y., Nakashima, K., Ichikawa, T., Tambo, Y., Taniguchi, H., et al. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101411
Real‐World Comparison of Dual Checkpoint Blockade and Immunotherapy Plus TKIs in Metastatic RCC
Ohba, K., Oki, M., Matsuda, T., Miyata, H., Kikuchi, H., Inoue, T., Shin, T., Sekine, Y., Narita, S., Naito, S., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72265
Dong, J., & Zhou, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1948343
Rotolo, R. (n.d.) · Institutional Research Information System University of Turin (University of Turin)
Metadata
- Authors
- Shi, L. Z., Fu, T., Guan, B., Chen, J., Blando, J. M., Allison, J. P., Xiong, L., Subudhi, S. K., Gao, J., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Nature Communications
- Published
- 2016-08-08
- Volume
- 7
- Issue
- 1
- Pages
- 12335-12335
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4979067
- OpenAlex
- W2519263052
- Cited by
- 111
- References
- 60
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 9 · 2022: 18 · 2021: 15 · 2020: 15 · 2019: 12 · 2018: 9 · 2017: 10 · 2016: 2
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Parker Institute for Cancer Immunotherapy
- National Institutes of Health (SU2C-CRI)
- University of Texas MD Anderson Cancer Center
- Stand Up To Cancer
- National Cancer Institute (R01 CA1633793, R01CA163793, CA1633793, P30CA016672)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, anti-PD-1 therapy, combination immunotherapy, tumor-infiltrating T cells, IFN-gamma receptor, immune checkpoint blockade, antitumor immunity, tumor immunosuppression, biomarkers
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms, Female, Humans, Immunologic Memory, Interferon-gamma, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, T-Lymphocytes, Signal Transduction, Interleukin-7, Up-Regulation, Lymphocytes, Tumor-Infiltrating, Receptors, Interleukin-7, Cell Line, Tumor, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.